Article Details

Tempest set to storm the HCC landscape with promising Phase II amezalpat data

Retrieved on: 2024-08-21 19:24:57

Tags for this article:

Click the tags to see associated articles and topics

Tempest set to storm the HCC landscape with promising Phase II amezalpat data. View article details on hiswai:

Excerpt

... AstraZeneca's Imfinzi (durvalumab) + Imjudo (tremelimumab) and Bristol Myers Squibb's Opdivo (nivolumab) + Yervoy (ipilimumab). According to ...

Article found on: www.clinicaltrialsarena.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up